Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 5/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18302136 | 0.98 | EPHB3 (0.47) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| Hypochlorous Acid SCHEMBL20240125 | 0.97 | EPHB3 (0.49) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| SCHEMBL11300658 | 0.82 | EPHB3 (0.55) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| SCHEMBL956445 | 0.82 | EPHB3 (0.48) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| Carbamic Acid SCHEMBL16050080 | 0.77 | NPC1 (0.53) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| SCHEMBL416200 | 0.76 | EPHB3 (0.56) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL19119427 | 0.75 | EPHB3 (0.55) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| SCHEMBL1044120 | 0.75 | EPHB3 (0.58) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL30152645 | 0.75 | EPHB3 (0.55) | EPHB3RIPK2LCKALDH1A1KDM4E | |
| SCHEMBL1286674 | 0.75 | NPC1 (0.68) | EPHB3RIPK2LCKALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119998281-A | Neurotrophic receptor tyrosine kinase (NTRK) inhibitors and methods of use thereof | 贝勒医学院 | 2025-05-13 | — | — | CN | claimed |
| US-20260049077-A1 | Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same | BAYLOR COLLEGE MEDICINE (US) | 2026-02-19 | — | — | US | disclosed |
| CN-119998281-A | Neurotrophic receptor tyrosine kinase (NTRK) inhibitors and methods of use thereof | 贝勒医学院 | 2025-05-13 | — | — | CN | disclosed |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | ALMIRALL, S.A. (ES) | 2020-09-01 | — | — | US | disclosed |
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2018-06-14 | — | — | US | disclosed |
| EP-3307272-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | Almirall, S.A. (ES) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016198663-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2016-12-15 | — | — | WO | disclosed |
| WO-2015086693-A1 | PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162856-A1 | 2-(PYRAZOLOPYRIDIN-3-YL)PYRIMIDINE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK3, JAK1 | EPHB3 2779/4885RIPK2 225/4885LCK 52/4885 |
| US-10759793-B2 | 2-(pyrazolopyridin-3-yl)pyrimidine derivatives as JAK inhibitors | JAK2, JAK3, JAK1 | EPHB3 2779/4885RIPK2 225/4885LCK 52/4885 |
| US-20260049077-A1 | Neurotrophic Receptor Tyrosine Kinase (NTRK) Inhibitors and Methods Using Same | NTRK2, NTRK3, NTRK1 | EPHB3 66/4885RIPK2 1204/4885LCK 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.